Christopher Raymond
Stock Analyst at Piper Sandler
(3.37)
# 1,019
Out of 5,084 analysts
138
Total ratings
51.33%
Success rate
2.38%
Average return
Main Sectors:
Stocks Rated by Christopher Raymond
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| ARDX Ardelyx | Maintains: Neutral | $9 → $10 | $5.87 | +70.36% | 10 | Nov 4, 2025 | |
| TSHA Taysha Gene Therapies | Initiates: Strong Buy | $13 | $5.06 | +156.92% | 3 | Oct 21, 2025 | |
| MGTX MeiraGTx Holdings | Initiates: Strong Buy | $29 | $8.58 | +238.00% | 2 | Oct 21, 2025 | |
| ABBV AbbVie | Maintains: Overweight | $231 → $284 | $228.71 | +24.17% | 13 | Oct 10, 2025 | |
| ABVX ABIVAX Société Anonyme | Maintains: Overweight | $42 → $70 | $109.64 | -36.15% | 2 | Jul 23, 2025 | |
| BIIB Biogen | Maintains: Neutral | $135 → $115 | $181.82 | -36.75% | 21 | Apr 29, 2025 | |
| ALXO ALX Oncology Holdings | Maintains: Overweight | $8 → $9 | $1.38 | +552.17% | 6 | Mar 6, 2025 | |
| BMRN BioMarin Pharmaceutical | Maintains: Overweight | $122 → $126 | $53.82 | +134.14% | 15 | Feb 20, 2025 | |
| QTTB Q32 Bio | Downgrades: Neutral | $20 → $4 | $3.56 | +12.36% | 3 | Feb 11, 2025 | |
| VRTX Vertex Pharmaceuticals | Maintains: Overweight | $535 → $533 | $457.26 | +16.56% | 8 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $1,195 → $1,013 | $722.83 | +40.14% | 7 | Jan 27, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $135 → $140 | $36.60 | +282.51% | 5 | Jan 13, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $72 | $79.63 | -9.58% | 1 | Jan 10, 2025 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $3 → $13 | $3.04 | +328.34% | 2 | Nov 18, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $60 → $75 | $5.89 | +1,173.34% | 4 | Nov 6, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $66 → $76 | $9.61 | +690.84% | 7 | Sep 23, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $10 | $0.68 | +1,363.59% | 2 | Sep 3, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $33 | $21.97 | +50.22% | 1 | Aug 15, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $22 | $39.36 | -44.11% | 1 | Jun 12, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Overweight | $2 → $4 | $1.60 | +150.78% | 3 | May 31, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Overweight | $293 → $288 | $340.33 | -15.38% | 16 | Apr 28, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $41 | $27.43 | +49.47% | 1 | Feb 3, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $28 | $46.51 | -39.80% | 1 | Jul 26, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Overweight | $40 | $107.05 | -62.63% | 1 | Aug 23, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Neutral | $90 | $5.93 | +1,418.99% | 1 | Jul 12, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Neutral | $96 | $2.04 | +4,617.44% | 2 | Mar 13, 2020 |
Ardelyx
Nov 4, 2025
Maintains: Neutral
Price Target: $9 → $10
Current: $5.87
Upside: +70.36%
Taysha Gene Therapies
Oct 21, 2025
Initiates: Strong Buy
Price Target: $13
Current: $5.06
Upside: +156.92%
MeiraGTx Holdings
Oct 21, 2025
Initiates: Strong Buy
Price Target: $29
Current: $8.58
Upside: +238.00%
AbbVie
Oct 10, 2025
Maintains: Overweight
Price Target: $231 → $284
Current: $228.71
Upside: +24.17%
ABIVAX Société Anonyme
Jul 23, 2025
Maintains: Overweight
Price Target: $42 → $70
Current: $109.64
Upside: -36.15%
Biogen
Apr 29, 2025
Maintains: Neutral
Price Target: $135 → $115
Current: $181.82
Upside: -36.75%
ALX Oncology Holdings
Mar 6, 2025
Maintains: Overweight
Price Target: $8 → $9
Current: $1.38
Upside: +552.17%
BioMarin Pharmaceutical
Feb 20, 2025
Maintains: Overweight
Price Target: $122 → $126
Current: $53.82
Upside: +134.14%
Q32 Bio
Feb 11, 2025
Downgrades: Neutral
Price Target: $20 → $4
Current: $3.56
Upside: +12.36%
Vertex Pharmaceuticals
Jan 27, 2025
Maintains: Overweight
Price Target: $535 → $533
Current: $457.26
Upside: +16.56%
Jan 27, 2025
Maintains: Overweight
Price Target: $1,195 → $1,013
Current: $722.83
Upside: +40.14%
Jan 13, 2025
Maintains: Overweight
Price Target: $135 → $140
Current: $36.60
Upside: +282.51%
Jan 10, 2025
Initiates: Overweight
Price Target: $72
Current: $79.63
Upside: -9.58%
Nov 18, 2024
Upgrades: Overweight
Price Target: $3 → $13
Current: $3.04
Upside: +328.34%
Nov 6, 2024
Maintains: Overweight
Price Target: $60 → $75
Current: $5.89
Upside: +1,173.34%
Sep 23, 2024
Maintains: Overweight
Price Target: $66 → $76
Current: $9.61
Upside: +690.84%
Sep 3, 2024
Maintains: Overweight
Price Target: $10
Current: $0.68
Upside: +1,363.59%
Aug 15, 2024
Initiates: Overweight
Price Target: $33
Current: $21.97
Upside: +50.22%
Jun 12, 2023
Maintains: Overweight
Price Target: $22
Current: $39.36
Upside: -44.11%
May 31, 2023
Upgrades: Overweight
Price Target: $2 → $4
Current: $1.60
Upside: +150.78%
Apr 28, 2023
Maintains: Overweight
Price Target: $293 → $288
Current: $340.33
Upside: -15.38%
Feb 3, 2023
Initiates: Overweight
Price Target: $41
Current: $27.43
Upside: +49.47%
Jul 26, 2022
Initiates: Overweight
Price Target: $28
Current: $46.51
Upside: -39.80%
Aug 23, 2021
Initiates: Overweight
Price Target: $40
Current: $107.05
Upside: -62.63%
Jul 12, 2021
Initiates: Neutral
Price Target: $90
Current: $5.93
Upside: +1,418.99%
Mar 13, 2020
Downgrades: Neutral
Price Target: $96
Current: $2.04
Upside: +4,617.44%